Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Total Liabilities (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Total Liabilities for 16 consecutive years, with $12.3 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 20.88% to $12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Dec 2025, down 20.88% year-over-year, with the annual reading at $12.3 million for FY2025, 20.88% down from the prior year.
  • Total Liabilities for Q4 2025 was $12.3 million at Plus Therapeutics, down from $13.6 million in the prior quarter.
  • The five-year high for Total Liabilities was $35.7 million in Q1 2025, with the low at $7.3 million in Q2 2025.
  • Average Total Liabilities over 5 years is $13.3 million, with a median of $11.7 million recorded in 2022.
  • Peak annual rise in Total Liabilities hit 241.34% in 2025, while the deepest fall reached 61.16% in 2025.
  • Over 5 years, Total Liabilities stood at $10.0 million in 2021, then surged by 74.31% to $17.4 million in 2022, then fell by 26.9% to $12.7 million in 2023, then grew by 22.35% to $15.6 million in 2024, then decreased by 20.88% to $12.3 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $12.3 million, $13.6 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.